Cocrystal Pharma (COCP) Stock Price, News & Analysis

Company Overview

Cocrystal Pharma, Inc. (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections. Lead projects target influenza A and B polymerases as well as key enzymes in coronaviruses such as SARS-CoV-2. Additional research efforts are directed at antiviral targets in hepatitis B virus, norovirus and other emerging viral threats, reflecting Cocrystal’s commitment to addressing a broad spectrum of infectious diseases.

Founded in 2006 and headquartered in Bothell, Washington, Cocrystal Pharma leverages collaborations with academic institutions and contract research organizations to expand its drug discovery capabilities. The company maintains research laboratories in the Seattle area and operates a business development office in New York City to engage with strategic partners and investors globally.

Under the leadership of founder and Chief Executive Officer Kenneth T. Hitchcock, Ph.D., Cocrystal Pharma seeks to address unmet medical needs in antiviral therapy. By combining deep structural biology expertise with a scalable discovery engine, the company aims to advance novel antivirals poised to combat both seasonal outbreaks and future pandemic threats.

Key Stats

• Today's Range: $0.82 to $0.89
• 50-Day Range: $0.82 to $1.15
• 52-Week Range: $0.76 to $2.67
• Volume: 34,120 shs
• Average Volume: 27,642 shs
• Market Capitalization: $11.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Cocrystal Pharma Stock Analysis - MarketRank™

Cocrystal Pharma scored higher than 5% of companies evaluated by MarketBeat, and ranked 870th out of 894 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Cocrystal Pharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Cocrystal Pharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cocrystal Pharma are expected to grow in the coming year, from ($0.69) to ($0.64) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cocrystal Pharma is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cocrystal Pharma is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cocrystal Pharma has a P/B Ratio of 1.78. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.73% of the float of Cocrystal Pharma has been sold short.

Short Interest Ratio / Days to Cover

Cocrystal Pharma has a short interest ratio ("days to cover") of 14.86, which indicates bearish sentiment.

Change versus previous month

Short interest in Cocrystal Pharma has recently decreased by 2.34%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cocrystal Pharma does not currently pay a dividend.

Dividend Growth

Cocrystal Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for COCP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added Cocrystal Pharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cocrystal Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

39.40% of the stock of Cocrystal Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

6.72% of the stock of Cocrystal Pharma is held by institutions.

Company Calendar

• Last Earnings: 5/15/2026
• Today: 8/02/2026
• Next Earnings (Estimated): 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:COCP
• CIK: 1412486
• Web: www.cocrystalpharma.com
• Phone: (305) 425-1780
• Fax: N/A
• Employees: 10
• Year Founded: 2004

Profitability

• EPS (Trailing Twelve Months): ($0.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.83 million
• Net Margins: N/A
• Pretax Margin: -3,924.00%
• Return on Equity: -150.61%
• Return on Assets: -97.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.66
• Quick Ratio: 2.66

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.46 per share
• Price / Book: 1.78

Miscellaneous

• Outstanding Shares: 13,790,000
• Free Float: 8,355,000
• Market Cap: $11.31 million
• Optionable: Not Optionable
• Beta: 1.43